Get the latest tech news
Wegovy and Ozempic (semaglutide) associated with reduction in alcohol addiction
Stories of GLP-1 drugs like Ozempic, Wegovy, Zepbound, and Mounjaro reducing patients’ desire to drink alcohol have been showing up everywhere. Now a new study in Nature Communications finds a 50-56% decrease in the risk of new or recurring alcohol addictions
The huge reduction in risk for first-time AUD diagnoses highlights the remarkable preventative effect that GLP-1s are able to provide because they are so widely prescribed— stopping addictions before they start. Dr. Rong Xu at Case Western and Dr. Nora Volkow, who runs the National Institute of Drug Abuse, are the corresponding authors for the study, which is based on patient health records and published in Nature Communications. Ozempic and Wegovy are GLP-1RA diabetes and obesity treatments that are now being studied for a wide range of other positive health effects, including Parkinson’s disease, Alzheimer’s, depression, anxiety, sleep apnea, and more.
Or read this on Hacker News
